Blood and Lymph Conditions

All Conditions

Nutritional and Metabolic Diseases

Anemia

Anemia, Iron-Deficiency

Iron Deficiencies

Hematologic Diseases

Metabolic Diseases

Iron Metabolism Disorders

Anemia, Hypochromic

Micronutrients

All Drugs and Chemicals

Iron

Ferinject will be administered once at inclusion

Ferinject

DELPHINE CORNUAULT-FOUBERT, MD

In oncology, anemia is a frequent symptom, leading to complication of patient management for, more or less, a long term but often poorly evaluated by medical teams.

In oncology, anemia is induced by multiple causes. Iron deficiency appears to be a leading cause of anemia, especially in people with solid cancer. Iron deficiency is characterized by a low level of iron . Iron is a trace element required for life. It is a major component of hemoglobin allowing the transport of oxygen in red blood cells. There are in fact 2 types of iron deficiency: an absolute iron deficiency with a deficiency of true iron and a functional iron deficiency. Since end of January 2014, intravenous iron-based injections have been reclassified for cancer patients at ICO Paul Papin. The monitoring of iron deficiency with or without anemia is currently done in our institute, the ICO-Paul Papin. There is a procedure for the management of anemia with or without iron deficiency but there is still no traceability of treatments performed, their compliance or even their impact on the rate hemoglobin and the quality of life of patients during their treatment. This observatory also makes it possible to evaluate the impact of this treatment on the quality of life of the patients and thus allows them a personalized care of the tiredness during their treatment

The study is for patients with iron deficiency and / or anemia during treatment for cancer These patients will receive ferinject. Patients will perform functional assessments and complete quality of life questionnaires, when the ferinject will be injected, then at 1 month and 6 months.

Patients will be followed for 6 months in the study

Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer

Obtained with the quality of life with the FACT-An questionnaire.

Absolute iron deficiency is defined by a ferritin level \<300 μg / L and a transferrin saturation coefficient \<20%.

Functional iron deficiency is defined by a ferritin level \<800 μg / L and a Transferrin Saturation Coefficient \<20%.

Addition of proportion of iron deficiency

Symptomatic anemia is defined as hemoglobin \<12 g / dL associated with pallor and anoxic functional symptoms

Asymptomatic anemia is defined as hemoglobin \<12 g / dL without clinical signs.

Addition of proportion of asymptomatic anemia and symptomatic anemia

The diagnosis of malnutrition will be done by calculating BMI (\<18.5 si - 70 years old and \<21 from 70 years old)

Estimated by functional questionnaire (Berg Balanced Scale test)

Estimated by functional questionnaire (the Tinetti test)

Estimated by functional questionnaire (the Timed Up and Go test)

Estimated by functional questionnaire (the 6-minute walk test)

Estimated by functional questionnaire (the 1-minute sit-stand test)

Estimated by functional questionnaire (the climb and descent test of a staircase for 1 minute)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer	NCT03625661	Iron Deficiency...	Ferinject	18 Years -	Institut Cancerologie de l'Ouest
Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer	NCT03625661	Iron Deficiency...	Ferinject	18 Years -	Institut Cancerologie de l'Ouest

Spots Global Cancer Trial Database for treatment related cancer,iron deficiency